Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1124)	6/20/2005 11:50:38 PM
From: Jibacoa	Respond to of 3722

LSBC Is also trying to clim back above the $1 level after its June 1 L of $0.30 <g> It is trying also to avoid delisting from the NAZ because of its stock holder's equity of less than $10M The stock was up today 11.9% on moderate volume of 50Ks. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1124)	7/11/2005 2:45:59 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NRMX Closed some of its April 18 downgap last week and now it seems it will try to climb back above the $12 level As I mentioned before, it went over its June 6 H of 9.84 and traded as high as 11.77 two days after my comments.<g> Today is up about 4.5% on volume of 100,953 bigcharts.marketwatch.com It announced last week that it has completed recruitment of patients with AD for its PIII for Alzhemed. The trial is being conducted in 51 U.S. and 17 Canadian centers and it expects to start a PIII in Europe in the fall of 2005 also with the same number of AD patients (around 950 ) It also announced on June 30 that the FDA agreed to review its NDA for Fibrillex reviewing the efficacy and safety data from its PII/III. (Fibrillex is NRMX's drug candidate to treat Amyloidosis.) Bernard